Independent Rough Terrain Center and Kalmar Join Forces to Offer Global Support for RTCH Independent Rough Terrain Center (IRTC) teams up with Kalmar to enhance global distribution and service for the Rough Terrain Container Handler (RTCH), serving diverse industries.

Independent Rough Terrain Center and Kalmar Join Forces to Offer Global Support for RTCH #KALMAR #Rough_Terrain_Container_Handler #IRTC

New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions. Large-scale analysis of more than 400,000 patients 1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM)

#IRTC New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population

www.stocktitan.net/news/IRTC/new-data-at-th...

iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025 Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio ® long-term continuous monitoring (LTCM)– even in patients with frequent (i.e., daily) symptoms 1 Data from more

#IRTC iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025

www.stocktitan.net/news/IRTC/i-rhythm-techn...

iRhythm Technologies Announces Third Quarter 2025 Financial Results iRhythm (NASDAQ: IRTC) reported Q3 2025 revenue of $192.9M, up 30.7% YoY, and gross margin of 71.1% (+230 bps YoY). The company reported a Q3 2025 net loss of $5.2M (diluted loss $0.16) and an adjusted net loss of $2.0M (diluted loss $0.06), both substantially improved versus Q3 2024. Unrestricted cash, cash equivalents, and marketable securities were $565.2M as of September 30, 2025. Management increased full-year 2025 guidance to $735M–$740M revenue with an adjusted EBITDA margin of ~8.25%–8.75%. Company cited clinical publications and FDA submission activity for next-gen Zio MCT.

#IRTC iRhythm Technologies Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/IRTC/i-rhythm-techn...

#IRTC #12cdf997-bea7-4c19-a8d2-5525de2ef7d8 #earningscall-transcripts

Origin | Interest | Match

iRhythm Technologies Announces Second Quarter 2025 Financial Results iRhythm Technologies (NASDAQ: IRTC) reported strong Q2 2025 financial results, with revenue reaching $186.7 million, up 26.1% year-over-year. The company achieved a gross margin of 71.2%, representing a 130-basis point improvement from Q2 2024.Key operational highlights include record quarterly revenue driven by core long-term monitoring business growth, Zio AT demand, and progress in value-based care. The company formed a strategic partnership with Lucem Health for AI-driven arrhythmia detection and presented significant findings at ADA 2025 regarding cardiac arrhythmias in cardiometabolic populations.Despite revenue growth, IRTC reported a net loss of $14.2 million ($0.44 per share), improved from a $20.1 million loss year-over-year. The company raised its 2025 guidance, projecting full-year revenue of $720-730 million with adjusted EBITDA margin of 8.0-8.5%. [ "Revenue grew 26.1% year-over-year to $186.7 million", "Gross margin improved 130 basis points to 71.2%", "Strong cash position with $545.5 million in unrestricted cash and equivalents", "Net loss improved from $20.1M to $14.2M year-over-year", "Increased full-year 2025 revenue and adjusted EBITDA guidance", "Strategic AI partnership with Lucem Health for enhanced arrhythmia detection" ]

#IRTC iRhythm Technologies Announces Second Quarter 2025 Financial Results

www.stocktitan.net/news/IRTC/i-rhythm-techn...

New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease iRhythm Technologies (IRTC) presented new data at ADA 2025 revealing significant findings about cardiac arrhythmias in type 2 diabetes (T2D) and chronic kidney disease (CKD) patients. The study analyzed over 30 million U.S. adults, showing that of 8.8 million T2D patients, 1.1 million developed major arrhythmias, with 47% occurring post-diabetes diagnosis. In the T2D+CKD population of 3.2 million patients, 21% developed major arrhythmias, with 59% occurring before CKD diagnosis. The research highlighted that arrhythmias often precede major cardiovascular events (MACE), with 17% of patients experiencing MACE within three days of arrhythmia. The findings suggest that early detection of arrhythmias could be crucial for preventing complications, especially since previous data showed that fewer than one in five patients experience symptoms during arrhythmic episodes.

#IRTC New Data Presented at ADA 2025 Highlights Burden and Risk Associations of Cardiac Arrhythmias in Patients with Type 2 Diabetes and Chronic Kidney Disease

www.stocktitan.net/news/IRTC/new-data-prese...

iRhythm Technologies Announces First Quarter 2025 Financial Results iRhythm Technologies (NASDAQ: IRTC) reported strong Q1 2025 financial results with revenue of $158.7 million, up 20.3% year-over-year. The company achieved a gross margin of 68.8%, representing a 250-basis point increase from Q1 2024. Despite revenue growth, iRhythm posted a net loss of $30.7 million, though improved from $45.7 million loss in Q1 2024. Key operational highlights include expansion into Japan, strong Zio AT demand in the US and UK, and positive clinical study results showing superior arrhythmia detection rates. The company maintains a strong financial position with $520.6 million in cash and marketable securities. For full-year 2025, iRhythm raised guidance, projecting revenue between $690-700 million and adjusted EBITDA margin of 7.5-8.5%.

#IRTC iRhythm Technologies Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/IRTC/i-rhythm-techn...

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring iRhythm Technologies (NASDAQ:IRTC) presented new real-world data from the AVALON study at HRS2025, demonstrating the clinical superiority of their Zio long-term continuous monitoring (LTCM) service. The study analyzed 428,707 commercially insured patients, showing Zio LTCM achieved:- Highest diagnostic yield (26.5%) compared to other monitoring services- 2.04x higher likelihood of arrhythmia diagnosis vs. Holter monitors- Lowest likelihood of repeat testing within 180 days- Reduced cardiovascular events risk within 1 yearThe Zio LTCM service includes a patch-based ECG monitor capturing 14 days of continuous data and the ZEUS system with FDA-cleared AI algorithm. The study expands on previous CAMELOT findings in Medicare patients, now confirming benefits in younger, commercially insured populations (mean age: 46 years).

#IRTC iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring

www.stocktitan.net/news/IRTC/i-rhythm-prese...

Healthcare Tech Veteran Who Led iRhythm's Success Story Now Leads Brain Mapping Innovator Med-tech veteran Kevin King brings 30-year track record to accelerate Turing's brain mapping technology and FDA-cleared Bullsai platform. Full strategic vision inside.

#IRTC Turing Medical Names Transformative Med Tech Leader Kevin King as President and Chief Executive Officer

www.stocktitan.net/news/IRTC/turing-medical...

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection iRhythm Technologies (NASDAQ:IRTC) presented significant findings from two large real-world studies at ACC.25, analyzing over 1.1 million patients using Zio® long-term continuous monitoring (LTCM) devices. The research revealed critical limitations in traditional 24-48 hour Holter monitoring.Key findings show that 64% of actionable arrhythmias in patients with daily symptoms went undetected in the first 48 hours of monitoring. Non-daily symptom patients showed higher arrhythmia yield (80.9%) compared to daily-symptom patients (69.1%). The study also found that less than 20% of patients documented symptoms coinciding with arrhythmic episodes, and over half of atrial fibrillation cases were asymptomatic.The research challenges conventional monitoring approaches and supports the benefits of Zio LTCM's extended 14-day monitoring period. With approximately 16 million Americans experiencing arrhythmias and undiagnosed atrial fibrillation costing the U.S. $3 billion annually, these findings have significant implications for clinical care and payer policies.

#IRTC iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

www.stocktitan.net/news/IRTC/i-rhythm-unvei...

Can iRhythm's 24% Revenue Jump and Record Customer Growth Signal a Healthcare Tech Breakthrough? Strong margin expansion and positive cash flow for third straight quarter showcase operational improvements alongside 20% full-year revenue growth to $592M.

#IRTC iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/IRTC/i-rhythm-techn...

iRhythm Surpasses 2024 Revenue Targets, Projects Strong 2025 Growth with Record Zio Monitor Adoption iRhythm exceeds FY2024 revenue guidance of $587.5M, achieves record new account openings for Zio monitor, and forecasts FY2025 revenue of $675-685M amid global expansion.

#IRTC iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/IRTC/i-rhythm-techn...

JUST IN: ( NASDAQ: #IRTC ) Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Shareholders to Learn More About the Investigation

#IRTC iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference

www.stocktitan.net/news/IRTC/i-rhythm-techn...

#IRTC iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring

www.stocktitan.net/news/IRTC/i-rhythm-data-...

NEWS: ( NASDAQ: #IRTC ) Outperform Recommendation Issued On IRTC By Oppenheimer

#StockMarket #News

News; ( NASDAQ: #IRTC ) Buy Recommendation Issued On IRTC By BTIG

#StockMarket #News

News; ( NASDAQ: #IRTC ) iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring

#StockMarket #News

News; ( NASDAQ: #IRTC ) iRhythm Technologies Expands Global Reach with the Launch of Zio Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain

#StockMarket #News